Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Chronic atrial fibrillation

3

Unknown

2,596

Pain

619

Cancer

609

Hypertension

575

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Previously Marketed

2

US Approved Rx

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Sodium/potassium-transporting ATPase

3

6-phosphogluconate dehydrogenase, decarboxylating

1

Glucose-6-phosphate 1-dehydrogenase

1

Glutathione reductase

1

Y79

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1954

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

Diagnostic

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Withering, W.

2

Alexandria

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

CHEBI

3

ChEMBL

3

DAILYMED

3

DRUG BANK

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

CARDIAC THERAPY

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

CARDIAC GLYCOSIDES

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Digitalis glycosides

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Digoxin

73K4184T59

Export Data
Search for Structure

Status:

US Approved Rx (2002)

First approved in 1954

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Sodium/potassium-transporting ATPase

6-phosphogluconate dehydrogenase, decarboxylating

Glucose-6-phosphate 1-dehydrogenase

Glutathione reductase

Conditions:

Chronic atrial fibrillation

Digoxin, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Digoxin inhibits...

the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium. The sodium calcium exchanger (NCX) in turn tries to extrude the sodium and in so doing, pumps in more calcium. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.

Digitoxin

E90NZP2L9U

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1954

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Sodium/potassium-transporting ATPase

Conditions:

Chronic atrial fibrillation

Digoxin is a cardiac glycoside derived from the purple foxglove flower. In 1785, the English chemist, botanist, and physician Sir William Withering published his findings that Digitalis purpurea could be used to treat cardiac dropsy (congestive heart...

failure; CHF). Digoxin has been in use for many years, but was not approved by the FDA for treatment of heart failure (HF) until the late 1990s. Another FDA indication for digoxin is atrial fibrillation (AF). Digoxin also has numerous off-label uses, such as in fetal tachycardia, supra-ventricular tachycardia, cor pulmonale, and pulmonary hypertension. Digitoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also has Para sympathomimetic properties. By increasing vagal tone in the sinoatrial and atrioventricular (AV) nodes, it slows the heart rate and AV nodal conduction.

ACETYLDIGITOXIN

0ZV4Q4L2FU

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1954

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Sodium/potassium-transporting ATPase

Conditions:

Chronic atrial fibrillation

Digoxin is a cardiac glycoside derived from the purple foxglove flower. In 1785, the English chemist, botanist, and physician Sir William Withering published his findings that Digitalis purpurea could be used to treat cardiac dropsy (congestive heart...

failure; CHF). Digoxin has been in use for many years, but was not approved by the FDA for treatment of heart failure (HF) until the late 1990s. Another FDA indication for digoxin is atrial fibrillation (AF). Digoxin also has numerous off-label uses, such as in fetal tachycardia, supra-ventricular tachycardia, cor pulmonale, and pulmonary hypertension. Digitoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also has Para sympathomimetic properties. By increasing vagal tone in the sinoatrial and atrioventricular (AV) nodes, it slows the heart rate and AV nodal conduction.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1